1. Search Result
Search Result
Results for "

nerve stimulation

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

1

Peptides

4

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N11004

    Others Neurological Disease
    Erinacine C is a potent stimulator. Erinacine C can be used for nerve-growth factor synthesis .
    Erinacine C
  • HY-W129456

    Others Neurological Disease
    Isaxonine acts as a modifier of the surface pH of the bilayer . Isaxonine accelerates the rate of peripheral nerve regeneration, stimulate axonal sprouting and promote motor and sensory function recovery . Isaxonine is a neurotrophic agent .
    Isaxonine
  • HY-N8028
    Quercetin 3-O-sambubioside
    1 Publications Verification

    Others Cancer
    Quercetin-3-O-sambubioside is a monomeric compound found in Eucommia ulmoides male flowers. Quercetin-3-O-sambubioside promotes the stimulation of the nerve center. Antioxidant and anticancer activities .
    Quercetin 3-O-sambubioside
  • HY-W027553

    NIK-247 free base

    Cholinesterase (ChE) Potassium Channel Sodium Channel Neurological Disease Metabolic Disease
    Ipidacrine is orally active and brain-penetrant AChE and BuChE inhibitors with IC50 values of 1 μM and 1.9 μM, respectively, which is also a partial agonist of M2-cholinergic receptors and a reversible cholinesterase inhibitor. Ipidacrine has a stimulating effect on neuromuscular transmission and excitation along the nerve fibres with a moderately anti-pain effect. Ipidacrine is an aminopyridines and is structurally similar to Tacrine (HY-111338). Ipidacrine is effective in various amnesia models, improves erectile function and inhibits K + and Na +-channels in the neuronal membrane in diabetic rats. Ipidacrine is promising for research of Alzheimer’s disease, ischaemic stroke, idiopathic neuropathy of the facial nerve, diabetes mellitus-induced erectile dysfunction and other deficits in central or peripheral cholinergic deseases .
    Ipidacrine
  • HY-110304

    mGluR Neurological Disease
    NPEC-caged-LY379268 is a type II mGluR agonist .
    NPEC-caged-LY379268
  • HY-N12566

    Others Neurological Disease
    Erinacin B is a active product that can be extracts from the mycelia of Hericium erinaceum. Erinacin B shows potent stimulating activity of nerve growth factor (NGF)-synthesis .
    Erinacin B
  • HY-105747A

    N-(3-Phenoxypropyl)guanidine nitrate; (3-Phenoxypropyl)guanidine nitrate

    Others Infection Neurological Disease
    Guanoxyfen (N-(3-Phenoxypropyl)guanidine) nitrate is a compound that exhibits potent inhibitory activity against the serine protease enzyme TMPRSS2, which plays a crucial role in the infectivity of coronaviruses. Guanoxyfen nitrate is also an effective inhibitor of vasoconstrictor responses to sympathetic nerve stimulation.
    Guanoxyfen nitrate
  • HY-14149A

    R 51619 monohydrate; (±)-Cisaprid monohydrate

    5-HT Receptor Neurological Disease Metabolic Disease
    Cisapride monohydrate is an orally and potent 5-HT4 receptor agonist and hERG inhibitor. Cisapride monohydrate is an prokinetic agent which facilitates or restores motility throughout the length of the gastrointestinal tract. Cisapride monohydrate stimulates gastrointestinal motor activity through an indirect mechanism involving the release of acetylcholine mediated by postganglionic nerve endings in the myenteric plexus of the gut .
    Cisapride monohydrate
  • HY-U00079A

    FK-176

    mAChR Neurological Disease
    Vamicamide (FK-176) is an orally active competitive mAChR antagonist that inhibits contractions induced by cholinergic nerve stimulation by preventing mAChR agonists from binding to mAChR. Vamicamide exhibits a good anti-bladder spasm effect, with a pA2 value of 6.82 in bladder tissue. Vamicamide can be used in research within the field of neurological diseases .
    Vamicamide
  • HY-N0667R

    Endogenous Metabolite Neurological Disease Cancer
    L-Asparagine (Standard) is the analytical standard of L-Asparagine. This product is intended for research and analytical applications. L-Asparagine ((-)-Asparagine) is a non-essential amino acid involved in the metabolic control of nerve and brain tissue cell function. L-Asparagine has antitumor activity . In Vitro:L-Asparagine (0.03 mM) can reverse the proliferation decline of six human cancer cells induced by ASNS siRNA knockdown .
    L-Asparagine (10 mM, 4 h) can stimulate ODC activity and proliferation in IPEC-J2 cells .
    L-Asparagine (Standard)
  • HY-16094

    BW 467C60

    Adrenergic Receptor Neurological Disease
    Bethanidine sulfate and its ortho-chloro derivative (BW 392C60) are potent adrenergic neurone blockers with sympathomimetic effects similar to bretylium and guanethidine in various animal models, particularly in cats. They inhibit the release of noradrenaline during nerve stimulation and enhance smooth muscle responses to adrenaline and noradrenaline. Bethanidine sulfate increases pressor responses to tyramine, though this effect diminishes with higher doses. Unlike guanethidine, Bethanidine sulfate does not deplete pressor amine content in the iris of cats post-administration. It also briefly inhibits autonomic cholinergic mechanisms and causes temporary neuromuscular paralysis in large doses, contrasting with its prolonged adrenergic neurone blocking effects .
    Bethanidine sulfate
  • HY-103247

    Angiotensin Receptor Cardiovascular Disease
    EMD 66684 is an antagonist of Angiotensin II Type 1 (AT1) receptor. EMD 66684 shows potent binding affinities for the AT1 subtype Ang II receptor with an IC50 value of 0.7 nM. EMD 66684 also serves as an antiischemic cytoprotectant - .
    EMD 66684
  • HY-136625

    Others Neurological Disease
    LY134046 is an inhibitor of norepinephrine N-methyltransferase (NMT). Its cardiovascular activity was studied in anesthetized spontaneously hypertensive rats (SHR). Acute intraperitoneal injection of 10 and 20 mg/kg of LY134046 caused minimal cardiovascular changes, while 40 mg/kg resulted in a sustained decrease in mean arterial blood pressure and heart rate. This hypotension and bradycardia occurred rapidly and occurred when brain NMT activity was significantly inhibited. However, norepinephrine concentrations in rat brains were not significantly reduced at the time when LY134046-induced blood pressure and heart rate effects were maximal. The acute cardiovascular activity of LY134046 was not significantly affected by pretreatment of SHR with phentolamine, propranolol, or atropine, and LY134046 reduced heart rate in suspended SHR. In addition, acute or chronic administration of LY134046 did not antagonize the vasoconstrictor responses induced by sympathetic nerve stimulation or exogenous norepinephrine. These observations suggest that LY134046 does not interact with adrenergic or cholinergic receptors and that its hypotensive and bradycardic effects do not require neurogenic tension. Chronic intraperitoneal administration of LY134046 (40 mg/kg/day) resulted in a sustained and significant inhibition of hypothalamic and brainstem NMT activity, leading to central norepinephrine depletion. During chronic treatment, norepinephrine and dopamine concentrations increased in the brainstem and hypothalamus of SHR. Despite chronic inhibition of central NMT and norepinephrine depletion, cardiovascular parameters in SHR treated groups were not significantly different from those in saline-injected controls. Chronic treatment with LY134046 did not result in tolerance to its central biochemical effects or acute cardiovascular activity. The present study does not support the idea that norepinephrine-producing neurons are involved in the central regulation of cardiovascular function, because the hypotension and bradycardia induced by acute administration of LY134046 occurred before a significant decrease in hypothalamic norepinephrine concentrations, whereas chronic inhibition of central NMT and depletion of norepinephrine resulted in minimal changes in baseline cardiovascular parameters.
    LY134046

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: